Cargando…
Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals
Real-world utilization of 4-factor prothrombin complex concentrate (4F-PCC) and plasma for the management of oral anticoagulant (OAC)-associated bleeding in US trauma hospitals was described. This is amulticenter, retrospective chart review evaluating the use of 4F-PCC and plasma in OAC reversal acr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272665/ https://www.ncbi.nlm.nih.gov/pubmed/37272033 http://dx.doi.org/10.1177/10760296231179682 |
_version_ | 1785059548219834368 |
---|---|
author | Refaai, Majed A. Bajcic, Paolo McNeill, Robert Hood, Christopher Milling, Truman J. |
author_facet | Refaai, Majed A. Bajcic, Paolo McNeill, Robert Hood, Christopher Milling, Truman J. |
author_sort | Refaai, Majed A. |
collection | PubMed |
description | Real-world utilization of 4-factor prothrombin complex concentrate (4F-PCC) and plasma for the management of oral anticoagulant (OAC)-associated bleeding in US trauma hospitals was described. This is amulticenter, retrospective chart review evaluating the use of 4F-PCC and plasma in OAC reversal across medical specialties. Physicians completed a survey and extracted data from 3 to 5 patient charts. Variables of interest included medical specialty, urgency, and bleed type. Two hundred and thirty-five physicians completed the survey, and 861 patient charts were included in the study. 4F-PCC was commonly used in life-threatening or emergent indications, whereas plasma was used in emergent and urgent indications. Plasma was used mostly for patients on warfarin (53% vs 47% 4F-PCC) and 4F-PCC for those on apixaban (82% vs 18% plasma) and rivaroxaban (77% vs 23% plasma). This retrospective analysis showed that 4F-PCC was predominantly used for OAC reversal despite available specific reversal agents for some of the OAC. Although it is not recommended by any reversal guidelines, plasma is still used for OAC reversal. Plasma should be avoided in the management of OAC-associated bleeding. |
format | Online Article Text |
id | pubmed-10272665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-102726652023-06-17 Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals Refaai, Majed A. Bajcic, Paolo McNeill, Robert Hood, Christopher Milling, Truman J. Clin Appl Thromb Hemost Original Manuscript Real-world utilization of 4-factor prothrombin complex concentrate (4F-PCC) and plasma for the management of oral anticoagulant (OAC)-associated bleeding in US trauma hospitals was described. This is amulticenter, retrospective chart review evaluating the use of 4F-PCC and plasma in OAC reversal across medical specialties. Physicians completed a survey and extracted data from 3 to 5 patient charts. Variables of interest included medical specialty, urgency, and bleed type. Two hundred and thirty-five physicians completed the survey, and 861 patient charts were included in the study. 4F-PCC was commonly used in life-threatening or emergent indications, whereas plasma was used in emergent and urgent indications. Plasma was used mostly for patients on warfarin (53% vs 47% 4F-PCC) and 4F-PCC for those on apixaban (82% vs 18% plasma) and rivaroxaban (77% vs 23% plasma). This retrospective analysis showed that 4F-PCC was predominantly used for OAC reversal despite available specific reversal agents for some of the OAC. Although it is not recommended by any reversal guidelines, plasma is still used for OAC reversal. Plasma should be avoided in the management of OAC-associated bleeding. SAGE Publications 2023-06-04 /pmc/articles/PMC10272665/ /pubmed/37272033 http://dx.doi.org/10.1177/10760296231179682 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Manuscript Refaai, Majed A. Bajcic, Paolo McNeill, Robert Hood, Christopher Milling, Truman J. Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals |
title | Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals |
title_full | Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals |
title_fullStr | Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals |
title_full_unstemmed | Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals |
title_short | Retrospective Analysis of the Real-World Utilization of 4-Factor Prothrombin Complex Concentrate and Plasma in Oral Anticoagulant-Associated Bleeding in US Hospitals |
title_sort | retrospective analysis of the real-world utilization of 4-factor prothrombin complex concentrate and plasma in oral anticoagulant-associated bleeding in us hospitals |
topic | Original Manuscript |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272665/ https://www.ncbi.nlm.nih.gov/pubmed/37272033 http://dx.doi.org/10.1177/10760296231179682 |
work_keys_str_mv | AT refaaimajeda retrospectiveanalysisoftherealworldutilizationof4factorprothrombincomplexconcentrateandplasmainoralanticoagulantassociatedbleedinginushospitals AT bajcicpaolo retrospectiveanalysisoftherealworldutilizationof4factorprothrombincomplexconcentrateandplasmainoralanticoagulantassociatedbleedinginushospitals AT mcneillrobert retrospectiveanalysisoftherealworldutilizationof4factorprothrombincomplexconcentrateandplasmainoralanticoagulantassociatedbleedinginushospitals AT hoodchristopher retrospectiveanalysisoftherealworldutilizationof4factorprothrombincomplexconcentrateandplasmainoralanticoagulantassociatedbleedinginushospitals AT millingtrumanj retrospectiveanalysisoftherealworldutilizationof4factorprothrombincomplexconcentrateandplasmainoralanticoagulantassociatedbleedinginushospitals |